Ceres Brain Therapeutics announces €6m financing

The spin-off from the French Atomic Energy Commission (CEA) said, the proceeds will support the set-up of a Phase I first-in-man trial of Ceres’ lead candidate CBT101, designed to treat neuronal metabolic defects associated with major neurological diseases, such as creatine transporter deficiency syndrome, amyotrophic lateral sclerosis (ALS) and Charcot’s disease.

The company’s pipeline also includes CBT201, for the treatment of tauopathies, and CBT301, a therapeutic antibody targeting brain tumours.

The fundraising, which was already carried out last October with the support of Bucéphale Finance (Julien Durand) and Axipiter (Constance le Vert) but only now announced, will enable Ceres Brain Therapeutics SA to strengthen its research team, particularly in the field of ALS, and expand its management team to prepare for strategic partnerships.

Ceres relies on its Creatine-to-Neurons™ approach to supply brain cells with creatine prodrug formulations and intra-nasal delivery to target the Nose-to-Brain pathway and finally the brain, particularly neurons. Clinical applications include rare genetic diseases characterised by a primary lack of cerebral creatine, conditions related to mitochondrial deficiencies, and epigenetic diseases.